C3AR1 is upregulated in AD and its selective targeting expected to modulate inflammation without adversely affecting other critical complement processes like phagocytosis and clearance (C3b) and the membrane attack complex (C5b/MAC). Here, C3AR1 is linked to Alzheimer disease.